Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
21 Oct 2021
21 Oct 2021
Historique:
pubmed:
28
4
2021
medline:
28
10
2021
entrez:
27
4
2021
Statut:
epublish
Résumé
Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.
Identifiants
pubmed: 33903916
doi: 10.2340/00015555-3816
pmc: PMC9425609
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00576Références
Curr Rheumatol Rep. 2018 May 30;20(7):43
pubmed: 29846817
J Am Acad Dermatol. 2014 Jan;70(1):146-67
pubmed: 24126079
J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1293-8
pubmed: 23057623
J Dermatolog Treat. 2018 Jun;29(4):334-346
pubmed: 29099667
N Engl J Med. 2015 Dec 24;373(26):2534-48
pubmed: 26699169
J Am Acad Dermatol. 2012 Feb;66(2):241-51
pubmed: 21752491
J Am Acad Dermatol. 2015 Sep;73(3):400-9
pubmed: 26092291
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514
pubmed: 29444376
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9
pubmed: 27663079
Br J Dermatol. 2018 Nov;179(5):1072-1080
pubmed: 29704432
J Am Acad Dermatol. 2014 Jul;71(1):141-50
pubmed: 24655820
Lancet. 2015 Sep 19;386(9999):1137-46
pubmed: 26135703
J Drugs Dermatol. 2018 Aug 1;17(8):918
pubmed: 30124735
J Am Acad Dermatol. 2003 Aug;49(2):271-5
pubmed: 12894076
Expert Opin Biol Ther. 2018 Jul;18(7):727-735
pubmed: 29798698
Am J Manag Care. 2016 Jun;22(8 Suppl):s216-24
pubmed: 27356193
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
Arch Intern Med. 2007 Aug 13-27;167(15):1670-5
pubmed: 17698691
J Dermatolog Treat. 2020 Aug;31(5):476-483
pubmed: 31557063
Br J Dermatol. 2019 Aug;181(2):413-414
pubmed: 31001812
Arch Dermatol. 2007 Jun;143(6):719-26
pubmed: 17576937
J Dermatolog Treat. 2015 Feb;26(1):23-31
pubmed: 24354461
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e32-e34
pubmed: 28695989
Arch Dermatol Res. 2014 Dec;306(10):921-5
pubmed: 25193345
J Dermatolog Treat. 2014 Feb;25(1):78-82
pubmed: 23875537
J Clin Aesthet Dermatol. 2016 Jun;9(6 Suppl 1):S3-S6
pubmed: 28439340
Autoimmun Rev. 2014 Sep;13(9):981-1000
pubmed: 25092612
Lancet. 2005 Oct 15-21;366(9494):1367-74
pubmed: 16226614
Patient Relat Outcome Meas. 2011 Jul;2:1-6
pubmed: 22915964
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):645-8
pubmed: 25370811
Front Immunol. 2014 Aug 12;5:368
pubmed: 25161652
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1161-1173
pubmed: 31785165
J Am Acad Dermatol. 2018 May;78(5):1019-1020
pubmed: 29180095
Br J Dermatol. 2017 Aug;177(2):411-418
pubmed: 28196270
Lancet. 2003 Apr 5;361(9364):1197-204
pubmed: 12686053
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
J Dermatolog Treat. 2003 Sep;14(3):158-65
pubmed: 14522626
PLoS One. 2018 May 17;13(5):e0195123
pubmed: 29771924
Br J Dermatol. 2020 Jan;182(1):67-75
pubmed: 30972746